Lehmann-Che J - Search Results

1

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Leroy B, et al. Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Cancer Res. 2017. PMID: 28254861 Free PMC article. Review.

2

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. Bertheau P, et al. PLoS Med. 2007 Mar;4(3):e90. doi: 10.1371/journal.pmed.0040090. PLoS Med. 2007. PMID: 17388661 Free PMC article.

3

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P. Varna M, et al. Int J Cancer. 2009 Feb 15;124(4):991-7. doi: 10.1002/ijc.24049. Int J Cancer. 2009. PMID: 19048622 Free article.

4

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

Manié E, Vincent-Salomon A, Lehmann-Che J, Pierron G, Turpin E, Warcoin M, Gruel N, Lebigot I, Sastre-Garau X, Lidereau R, Remenieras A, Feunteun J, Delattre O, de Thé H, Stoppa-Lyonnet D, Stern MH. Manié E, et al. Cancer Res. 2009 Jan 15;69(2):663-71. doi: 10.1158/0008-5472.CAN-08-1560. Cancer Res. 2009. PMID: 19147582

5

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de Thé H, Pusztai L. Coutant C, et al. Clin Cancer Res. 2011 Apr 15;17(8):2591-601. doi: 10.1158/1078-0432.CCR-10-1045. Epub 2011 Jan 19. Clin Cancer Res. 2011. PMID: 21248301

6

Distinct tumor protein p53 mutants in breast cancer subgroups.

Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H. Dumay A, et al. Int J Cancer. 2013 Mar 1;132(5):1227-31. doi: 10.1002/ijc.27767. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22886769 Free article.

7

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P. Bally C, et al. Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23. Leuk Res. 2014. PMID: 24836762

8

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.

Bally C, Renneville A, Preudhomme C, Legrand M, Adès L, de Thé H, Fenaux P, Lehmann-Che J. Bally C, et al. Leuk Res. 2015 Jul 4:S0145-2126(15)30344-1. doi: 10.1016/j.leukres.2015.07.001. Online ahead of print. Leuk Res. 2015. PMID: 26271412

9

Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S. Maslah N, et al. Haematologica. 2020 Jun;105(6):1539-1551. doi: 10.3324/haematol.2019.218453. Epub 2019 Sep 5. Haematologica. 2020. PMID: 31488557 Free PMC article.

10

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. Groheux D, et al. Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35. doi: 10.1007/s00259-010-1640-9. Epub 2010 Nov 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21057787 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page